Clinical Trial Update: SG2918 For Advanced Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 study update for SG2918 in patients with advanced malignancies. The trial is active but not recruiting, sponsored by Hangzhou Sumgen Biotech Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SG2918 (SG2918)

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Advanced Malignant Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING